Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference

Rhea-AI Summary

Viridian Therapeutics, Inc. (NASDAQ: VRDN) will participate in the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022. The conference will feature a fireside chat at 10:30 a.m. ET, available via a live webcast on the company's website. Viridian is focused on developing innovative treatments for serious diseases, notably through its monoclonal antibody programs targeting thyroid eye disease (TED). Key products include VRDN-001, VRDN-002, and VRDN-003, which offer convenient dosing options for patients suffering from TED.

WALTHAM, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that senior management will participate in the 5^th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022.   

Evercore ISI HealthCONx Conference
Format:	Fireside Chat
Date:	December 1, 2022
Time:	10:30 a.m. ET

The live webcast of the fireside chat will be accessible under "Events and Presentations” within “News and Events” on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcast will be available on the Company’s website after the event.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). VRDN-002 is a distinct anti-IGF-1R antibody and incorporates half-life extension technology. VRDN-003 is an extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003 are designed for administration as convenient, low-volume, subcutaneous injections. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Viridian is based in Waltham, Massachusetts.

Investor and Media Contact:
Todd James
Viridian Therapeutics, Inc.
Senior Vice President, Corporate Affairs and Investor Relations
IR@viridiantherapeutics.com 

FAQ

When will Viridian Therapeutics participate in the Evercore ISI HealthCONx Conference?

Viridian Therapeutics will participate in the Evercore ISI HealthCONx Conference on December 1, 2022.

What time is Viridian's fireside chat at the conference?

The fireside chat is scheduled for 10:30 a.m. ET on December 1, 2022.

How can I access the webcast of Viridian's fireside chat?

The live webcast will be accessible under 'Events and Presentations' on Viridian's website.

What is the focus of Viridian Therapeutics' product development?

Viridian Therapeutics focuses on advancing treatments for serious diseases, particularly thyroid eye disease (TED) with their monoclonal antibodies.

What are the key products developed by Viridian Therapeutics?

Viridian's key products include VRDN-001, VRDN-002, and VRDN-003, which target insulin-like growth factor-1 receptor for treating TED.